Why AbbVie Inc.'s Shares Slumped 13% in September

Risk of patent expiration on Humira and Gilead Sciences positive hepatitis C trial results weighed on shares last month.

Todd Campbell
Todd Campbell
Oct 6, 2015 at 1:00PM
Health Care

Amid a widespread industry sell-off, and in the wake of positive trial data from competitor Gilead Sciences (NASDAQ:GILD), shares in AbbVie, Inc (NYSE:ABBV) tumbled by 12.8% last month.

AbbVie is under pressure to overcome looming headwinds tied to the fast-approaching patent expiration on its top selling drug, Humira, but its unclear whether its efforts will succeed. In the following slideshow, I highlight the risks to AbbVie and how it hopes to overcome them. 


Why AbbVie Slumped 13% In September from The Motley Fool